{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-056912","form_type":"8-K","ticker":null,"cik":"0001828522","company_name":"eFFECTOR Therapeutics, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.465204+00:00","generated_at":"2026-06-02T06:55:43.563753+00:00","sec_items":["1.01","1.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"eFFECTOR Therapeutics enters $50M ATM equity facility with H.C. Wainwright; terminates prior Cantor agreement","bullets":["New ATM offering agreement allows sale of up to $50M in common stock via H.C. Wainwright; agent commission 3.0%.","Prior ATM agreement with Cantor Fitzgerald terminated; company had sold 1.075M shares for $9.8M under that program.","Sales under new agreement are at-the-market on Nasdaq; no obligation to sell any shares."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-056912","json":"https://secwatch.observer/filing/0000950170-24-056912.json","markdown":"https://secwatch.observer/filing/0000950170-24-056912.md","text":"https://secwatch.observer/filing/0000950170-24-056912.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1828522/000095017024056912/0000950170-24-056912-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1828522/000095017024056912/eftr-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T06:55:43.563753+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5372b006aacd44b160cee1bb322774fbcc22d7cc","claim":"eFFECTOR Therapeutics, Inc. terminated Controlled Equity Offering SM Sales Agreement with Cantor Fitzgerald & Co. (effective 2024-05-09).","evidence_excerpt":"On May 9, 2024, the Company terminated its Controlled Equity Offering SM Sales Agreement, dated September 1, 2022, with Cantor Fitzgerald & Co. (the “Prior Sales Agreement”), pursuant to which the Company was able sell shares of common stock in “at the market offerings” as defined by Rule 415 of the Securities Act.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1828522/000095017024056912/0000950170-24-056912-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"atm program"},{"label":"Counterparty","value":"Cantor Fitzgerald & Co."},{"label":"Effective","value":"2024-05-09"}],"fact_type":"material_agreement"},{"claim_id":"c7a02309b594d74e2a519aa119330ff993aaf226","claim":"eFFECTOR Therapeutics, Inc. entered into Sales Agreement with H.C. Wainwright & Co., LLC valued at up to $50.0 million (effective 2024-05-09).","evidence_excerpt":"On May 9, 2024, eFFECTOR Therapeutics, Inc. (the “Company”) entered into an At the Market Offering Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC (the “Agent”), under which the Company may, from time to time, sell shares of the Company’s common stock having an aggregate offering price of up to $50.0 million through the Agent.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1828522/000095017024056912/0000950170-24-056912-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"atm program"},{"label":"Counterparty","value":"H.C. Wainwright & Co., LLC"},{"label":"Value","value":"up to $50.0 million"},{"label":"Effective","value":"2024-05-09"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}